MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Schrodinger, Inc. (SDGR)

Schrodinger, Inc. (SDGR)

|||

Income Overview

Revenue
$58,587K
Net Income
-$60,026K
Net Profit Margin
-102.46%
EPS
-$0.81
Unit: Thousand (K) dollars
Revenue Breakdown
    • Drug Discovery
    • On Premise Software
    • Hosted Software
    • Others
Revenue Breakdown
    • Software Segment
    • Drug Discovery Segment
Revenue Breakdown
    • US
    • EMEA
    • APAC
    • Non Us

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
58,587 87,235 54,324 54,759
Software Products And Services
10,863 14,791* 11,111 13,029
Drug Discovery
16,310 15,151* 15,174 15,572
Contribution
1,867 NaN NaN NaN
Total cost of revenues
29,040 29,942 26,285 28,601
Gross profit
29,547 57,293 28,039 26,158
Research and development
43,824 41,399 42,757 43,138
Sales and marketing
11,603 10,338 9,524 10,734
General and administrative (includes related party expense of 165 and 109, respectively)
22,914 22,713 21,705 25,189
Total operating expenses
78,341 74,450 73,986 79,061
Loss from operations
-48,794 -17,157 -45,947 -52,903
Gain on equity investments
NaN 0 0 0
Change in fair value of equity investments
-13,487 46,999 9,691 4,579
Other income
2,663 3,131 3,623 5,438
Total other expense
-10,824 50,130 13,314 10,017
Gain before income taxes
-59,618 32,973 -32,633 -42,886
Income taxes (benefit) at statutory federal rate
NaN -5,372* NaN NaN
State and local taxes, net of federal income tax effect
NaN -12* NaN NaN
Foreign tax effects, other foreign
NaN -98* NaN NaN
Other
NaN 38* NaN NaN
General business credits
NaN 3,186* NaN NaN
Changes in valuation allowance
NaN 7,931* NaN NaN
Equity compensation
NaN 589* NaN NaN
Section 162 officer's compensation
NaN 318* NaN NaN
Other
NaN 136* NaN NaN
Changes in unrecognized tax benefits
NaN 1,248* NaN NaN
Transfer pricing
NaN -864* NaN NaN
Other, net
NaN -265* NaN NaN
Income tax expense
408 462 162 287
Net gain
-60,026 32,511 -32,795 -43,173
Basic EPS
-0.81 0.441 -0.45 -0.59
Diluted EPS
-0.81 0.441 -0.45 -0.59
Basic Average Shares
73,989,137 73,674,551 73,613,090 73,427,635
Diluted Average Shares
73,989,137 73,674,551 73,613,090 73,427,635
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

On PremiseSoftware$14,180K Hosted Software$12,080K Maintenance$6,662K Professional Services$2,638K Net gain-$60,026K (-0.36%↓ Y/Y)Software Products AndServices$35,560K Drug Discovery$22,879K Contribution$148K Gain before incometaxes-$59,618K (0.27%↑ Y/Y)Income tax expense$408K (1357.14%↑ Y/Y)Total revenues$58,587K (-1.62%↓ Y/Y)Loss from operations-$48,794K (4.12%↑ Y/Y)Total other expense-$10,824K (-21.74%↓ Y/Y)Gross profit$29,547K (-5.07%↓ Y/Y)Other income$2,663K (-36.66%↓ Y/Y)Total cost of revenues$29,040K (2.16%↑ Y/Y)Total operatingexpenses$78,341K (-4.48%↓ Y/Y)Change in fair value ofequity investments-$13,487K (-2.99%↓ Y/Y)Drug Discovery$16,310K Software Products AndServices$10,863K Contribution$1,867K Research and development$43,824K (-4.41%↓ Y/Y)General andadministrative (includes...$22,914K (-11.19%↓ Y/Y)Sales and marketing$11,603K (11.92%↑ Y/Y)